180 related articles for article (PubMed ID: 29866440)
1. PPARγ is dispensable for clear cell renal cell carcinoma progression.
Sanchez DJ; Steger DJ; Skuli N; Bansal A; Simon MC
Mol Metab; 2018 Aug; 14():139-149. PubMed ID: 29866440
[TBL] [Abstract][Full Text] [Related]
2. PPARγ is functionally expressed in clear cell renal cell carcinoma.
Collet N; Théoleyre S; Rageul J; Mottier S; Jouan F; Rioux-Leclercq N; Fergelot P; Patard JJ; Masson D; Denis MG
Int J Oncol; 2011 Mar; 38(3):851-7. PubMed ID: 21206970
[TBL] [Abstract][Full Text] [Related]
3.
Wu Y; Song T; Liu M; He Q; Chen L; Liu Y; Ni D; Liu J; Hu Y; Gu Y; Li Q; Zhou Q; Xie Y
DNA Cell Biol; 2019 Jul; 38(7):700-707. PubMed ID: 31090452
[TBL] [Abstract][Full Text] [Related]
4. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop.
Liu Y; Wang JX; Nie ZY; Wen Y; Jia XJ; Zhang LN; Duan HJ; Shi YH
J Exp Clin Cancer Res; 2019 Oct; 38(1):439. PubMed ID: 31747963
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
7. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma.
Zeng K; Li Q; Song G; Chen B; Luo M; Miao J; Liu B
Cell Signal; 2023 Oct; 110():110838. PubMed ID: 37541641
[TBL] [Abstract][Full Text] [Related]
8. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
9. The lncRNA SNHG5-mediated miR-205-5p downregulation contributes to the progression of clear cell renal cell carcinoma by targeting ZEB1.
Xiang W; Lv L; Zhou G; Wu W; Yuan J; Zhang C; Jiang G
Cancer Med; 2020 Jun; 9(12):4251-4264. PubMed ID: 32281285
[TBL] [Abstract][Full Text] [Related]
10. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
11. MFN2 suppresses the accumulation of lipid droplets and the progression of clear cell renal cell carcinoma.
Cai Z; Luo W; Wang H; Zhu R; Yuan Y; Zhan X; Xie M; Zhuang H; Chen H; Xu Y; Li X; Liu L; Xu G
Cancer Sci; 2024 Jun; 115(6):1791-1807. PubMed ID: 38480904
[TBL] [Abstract][Full Text] [Related]
12. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
[TBL] [Abstract][Full Text] [Related]
13. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
14. Glycogen metabolism is dispensable for tumour progression in clear cell renal cell carcinoma.
Xie H; Song J; Godfrey J; Riscal R; Skuli N; Nissim I; Simon MC
Nat Metab; 2021 Mar; 3(3):327-336. PubMed ID: 33758423
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
[TBL] [Abstract][Full Text] [Related]
16. G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression.
Zhang Q; Ni Y; Wang S; Agbana YL; Han Q; Liu W; Bai H; Yi Z; Yi X; Zhu Y; Sai B; Yang L; Shi Q; Kuang Y; Yang Z; Zhu Y
Int J Med Sci; 2022; 19(1):47-64. PubMed ID: 34975298
[No Abstract] [Full Text] [Related]
17. Comprehensive profiling of circRNAs and the tumor suppressor function of circHIPK3 in clear cell renal carcinoma.
Li H; Heng B; Ouyang P; Xie X; Zhang T; Chen G; Chen Z; Cheang K; Lai C
J Mol Histol; 2020 Jun; 51(3):317-327. PubMed ID: 32409849
[TBL] [Abstract][Full Text] [Related]
18. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
19. Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).
Wang W; Gan Z; Liu Q; Yan S; Mulati R; Wang Y
Bioengineered; 2021 Dec; 12(1):2957-2969. PubMed ID: 34180759
[TBL] [Abstract][Full Text] [Related]
20. CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Jiang N; Niu G; Pan YH; Pan W; Zhang MF; Zhang CZ; Shen H
EBioMedicine; 2020 Mar; 53():102692. PubMed ID: 32113161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
